KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Work In Process (2016 - 2024)

Historic Work In Process for Nektar Therapeutics (NKTR) over the last 12 years, with Q2 2024 value amounting to $10.6 million.

  • Nektar Therapeutics' Work In Process changed N/A to $10.6 million in Q2 2024 from the same period last year, while for Jun 2024 it was $10.6 million, marking a year-over-year change of. This contributed to the annual value of $12.9 million for FY2023, which is 1982.51% up from last year.
  • According to the latest figures from Q2 2024, Nektar Therapeutics' Work In Process is $10.6 million.
  • Over the past 5 years, Nektar Therapeutics' Work In Process peaked at $12.9 million during Q4 2023, and registered a low of $10.0 million during Q1 2024.
  • For the 3-year period, Nektar Therapeutics' Work In Process averaged around $11.3 million, with its median value being $10.7 million (2022).
  • Data for Nektar Therapeutics' Work In Process shows a peak YoY increase of 1982.51% (in 2023) and a maximum YoY decrease of 1982.51% (in 2023) over the last 5 years.
  • Nektar Therapeutics' Work In Process (Quarter) stood at $10.7 million in 2022, then increased by 19.83% to $12.9 million in 2023, then fell by 17.78% to $10.6 million in 2024.
  • Its last three reported values are $10.6 million in Q2 2024, $10.0 million for Q1 2024, and $12.9 million during Q4 2023.